Century Therapeutics, Inc. IPSC
We take great care to ensure that the data presented and summarized in this overview for Century Therapeutics, Inc. is accurate and up-to-date, based on a comprehensive analysis of 13F filing forms for institutional ownership and form 4 filings for insider transactions. Please note that this data may differ from other sources and should not be relied upon as the sole basis for investment decisions.
Top Institutions Holding IPSC
View all-
Bain Capital Life Sciences Investors, LLC Boston, MA5.41MShares$2.81 Million0.91% of portfolio
-
Black Rock Inc. New York, NY2.9MShares$1.51 Million0.0% of portfolio
-
Vanguard Group Inc Valley Forge, PA2.11MShares$1.1 Million0.0% of portfolio
-
Jim Simons Renaissance Technologies LLC | New York, Ny2.02MShares$1.05 Million0.0% of portfolio
-
Dafna Capital Management LLC Los Angeles, CA1.7MShares$886,2000.28% of portfolio
-
Casdin Capital, LLC New York, NY1.23MShares$638,6580.1% of portfolio
-
Syncona Portfolio LTD Guernsey, Channel Islands, X01.21MShares$630,7891.76% of portfolio
-
Tang Capital Management LLC San Diego, CA900KShares$468,0000.03% of portfolio
-
Israel Englander Millennium Management LLC | New York, Ny812KShares$422,3500.0% of portfolio
-
Two Sigma Investments, LP New York, NY573KShares$297,7220.0% of portfolio
Latest Institutional Activity in IPSC
Top Purchases
Top Sells
About IPSC
Century Therapeutics, Inc., a biotechnology company, develops transformative allogeneic cell therapies for the treatment of solid tumor and hematological malignancies. The company's lead product candidate is CNTY-101, an allogeneic, induced pluripotent stem cells (iPSCs)-derived chimeric antigen receptors (CAR)-iNK cell therapy targeting CD19 for relapsed, refractory B-cell lymphoma. It is also developing CNTY-103, a CAR-iNK candidate targeting CD133 + EGFR for recurrent glioblastoma; CNTY-102, a CAR-iT targeting CD19 + CD79b for relapsed, refractory B-cell lymphoma and other B-cell malignancies; CNTY-104, a CAR-iT or CAR-iNK multi-specific candidate for acute myeloid leukemia; and CNTY-106, a CAR-iNK or CAR-iT multi-specific candidate for multiple myeloma. Century Therapeutics, Inc. was founded in 2018 and is headquartered in Philadelphia, Pennsylvania.
Insider Transactions at IPSC
Insider Transaction List
View all| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|---|---|---|---|---|---|
|
Aug 14
2025
|
Brent Pfeiffenberger President and CEO |
BUY
Grant, award, or other acquisition
|
Direct |
1,587,614
+32.69%
|
-
|
|
Aug 04
2025
|
Douglas Carr SVP Finance & Operations |
SELL
Open market or private sale
|
Direct |
296
-0.07%
|
$0
$0.53 P/Share
|
|
Jun 09
2025
|
Brent Pfeiffenberger President and CEO |
SELL
Open market or private sale
|
Direct |
475
-0.03%
|
$0
$0.62 P/Share
|
|
Jun 09
2025
|
Adrienne Farid Chief Operations Officer |
SELL
Open market or private sale
|
Direct |
552
-0.22%
|
$0
$0.62 P/Share
|
|
Jun 09
2025
|
Douglas Carr SVP Finance & Operations |
SELL
Open market or private sale
|
Direct |
4,904
-1.19%
|
$0
$0.62 P/Share
|
|
Jun 09
2025
|
Gregory Russotti Officer |
SELL
Open market or private sale
|
Direct |
526
-0.13%
|
$0
$0.62 P/Share
|
|
May 16
2025
|
Brent Pfeiffenberger President and CEO |
SELL
Open market or private sale
|
Direct |
29,552
-1.73%
|
$0
$0.55 P/Share
|
|
May 05
2025
|
Douglas Carr SVP Finance & Operations |
SELL
Open market or private sale
|
Direct |
295
-0.07%
|
$0
$0.55 P/Share
|
|
May 05
2025
|
Adrienne Farid Chief Operations Officer |
SELL
Open market or private sale
|
Direct |
1,024
-0.41%
|
$0
$0.55 P/Share
|
|
Mar 11
2025
|
Brent Pfeiffenberger President and CEO |
BUY
Grant, award, or other acquisition
|
Direct |
521,500
+23.35%
|
-
|
|
Mar 11
2025
|
Chad Cowan Chief Scientific Officer |
BUY
Grant, award, or other acquisition
|
Direct |
19,500
+7.81%
|
-
|
|
Mar 11
2025
|
Morgan Conn Chief Finanical Officer |
BUY
Grant, award, or other acquisition
|
Direct |
19,500
+19.67%
|
-
|
|
Mar 11
2025
|
Douglas Carr SVP Finance & Operations |
BUY
Grant, award, or other acquisition
|
Direct |
95,625
+18.87%
|
-
|
|
Mar 11
2025
|
Adrienne Farid Chief Operations Officer |
BUY
Grant, award, or other acquisition
|
Direct |
120,000
+32.28%
|
-
|
|
Mar 11
2025
|
Gregory Russotti Officer |
BUY
Grant, award, or other acquisition
|
Direct |
120,000
+23.41%
|
-
|
|
Mar 10
2025
|
Brent Pfeiffenberger President and CEO |
SELL
Open market or private sale
|
Direct |
2,235
-0.19%
|
$0
$0.62 P/Share
|
|
Mar 10
2025
|
Douglas Carr SVP Finance & Operations |
SELL
Open market or private sale
|
Direct |
1,240
-0.39%
|
$0
$0.62 P/Share
|
|
Mar 10
2025
|
Adrienne Farid Chief Operations Officer |
SELL
Open market or private sale
|
Direct |
2,359
-1.76%
|
$0
$0.62 P/Share
|
|
Mar 10
2025
|
Gregory Russotti Officer |
SELL
Open market or private sale
|
Direct |
2,360
-0.86%
|
$0
$0.62 P/Share
|
|
Feb 18
2025
|
Brent Pfeiffenberger President and CEO |
SELL
Open market or private sale
|
Direct |
34,712
-2.83%
|
$0
$0.78 P/Share
|
Last 12 Months Summary
| Open market or private purchase | 5K shares |
|---|---|
| Grant, award, or other acquisition | 2.62M shares |
| Open market or private sale | 83.3K shares |
|---|---|
| Payment of exercise price or tax liability | 260K shares |